Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 115

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition

Cole, David K, Edwards, Emily S J, Wynn, Katherine K, Clement, Mathew, Miles, John J, Ladell, Kristin, Ekeruche, Julia, Gostick, Emma, Adams, Katherine J, Skowera, Ania, Peakman, Mark, Wooldridge, Linda, Price, David A, Sewell, Andrew K · 2010 · The Journal of Immunology

Abstract

Improving T cell Ags by altering MHC anchor residues is a common strategy used to enhance peptide vaccines, but there has been little assessment of how such modifications affect TCR binding and T cell recognition. In this study, we use surface plasmon resonance and peptide–MHC tetramer binding at the cell surface to demonstrate that changes in primary peptide anchor residues can substantially and unpredictably alter TCR binding. We also demonstrate that the ability of TCRs to differentiate between natural and anchor-modified heteroclitic peptides distinguishes T cells that exhibit a strong preference for either type of Ag. Furthermore, we show that anchor-modified heteroclitic peptides prime T cells with different TCRs compared with those primed with natural Ag. Thus, vaccination with heteroclitic peptides may elicit T cells that exhibit suboptimal recognition of the intended natural Ag and, consequently, impaired functional attributes in vivo. Heteroclitic peptide-based immune interventions therefore require careful evaluation to ensure efficacy in the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1000629

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 58

  1. Davis, 1988, T-cell antigen receptor genes and T-cell recognition, Nature, 334, 395, 10.1038/334395a0 · DOI · Paper page
  2. Garcia, 1999, Emerging principles for T cell receptor recognition of antigen in cellular immunity, Rev. Immunogenet., 1, 75
  3. Chen, 2005, Structural and kinetic basis for heightened immunogenicity of T cell vaccines, J. Exp. Med., 201, 1243, 10.1084/jem.20042323 · DOI · Paper page
  4. Keogh, 2001, Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity, J. Immunol., 167, 787, 10.4049/jimmunol.167.2.787 · DOI
  5. Laugel, 2007, Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties, J. Biol. Chem., 282, 23799, 10.1074/jbc.M700976200 · DOI · Paper page
  6. Parkhurst, 1996, Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues, J. Immunol., 157, 2539, 10.4049/jimmunol.157.6.2539 · DOI · Paper page
  7. Shang, 2009, Rational optimization of tumor epitopes using in silico analysis-assisted substitution of TCR contact residues, Eur. J. Immunol., 39, 2248, 10.1002/eji.200939338 · doi:10.1002/eji.200939338
  8. Terasawa, 2002, Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen, Clin. Cancer Res., 8, 41
  9. Valmori, 1998, Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J. Immunol., 160, 1750, 10.4049/jimmunol.160.4.1750 · DOI · Paper page
  10. La Rosa, 2001, Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries, Blood, 97, 1776, 10.1182/blood.V97.6.1776 · doi:10.1182/blood.v97.6.1776
  11. Udaka, 1995, Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries, J. Exp. Med., 181, 2097, 10.1084/jem.181.6.2097 · doi:10.1084/jem.181.6.2097
  12. Rammensee, 1995, MHC ligands and peptide motifs: first listing, Immunogenetics, 41, 178, 10.1007/BF00172063 · DOI · Paper page
  13. Rammensee, 1999, SYFPEITHI: database for MHC ligands and peptide motifs, Immunogenetics, 50, 213, 10.1007/s002510050595 · DOI · Paper page
  14. Parker, 1992, Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2, J. Immunol., 149, 3580, 10.4049/jimmunol.149.11.3580 · DOI · Paper page
  15. Hunt, 1992, Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry, Science, 255, 1261, 10.1126/science.1546328 · DOI · Paper page
  16. Peakman, 2001, Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?, Immunology, 104, 361, 10.1046/j.1365-2567.2001.01335.x · DOI
  17. Voskens, 2009, Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome, Curr. Mol. Med., 9, 683, 10.2174/156652409788970724 · doi:10.2174/156652409788970724
  18. Cole, 2007, Human TCR-binding affinity is governed by MHC class restriction, J. Immunol., 178, 5727, 10.4049/jimmunol.178.9.5727 · DOI · Paper page
  19. Rosenberg, 1998, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat. Med., 4, 321, 10.1038/nm0398-321 · DOI · Paper page
  20. Houghton, 2007, Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes, Vaccine, 25, 5330, 10.1016/j.vaccine.2007.05.008 · doi:10.1016/j.vaccine.2007.05.008
  21. Speiser, 2008, Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen, Proc. Natl. Acad. Sci. USA, 105, 3849, 10.1073/pnas.0800080105 · DOI
  22. Skowera, 2008, CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope, J. Clin. Invest., 118, 3390
  23. Lissina, 2009, Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers, J. Immunol. Methods, 340, 11, 10.1016/j.jim.2008.09.014 · DOI
  24. Cole, 2009, Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor, J. Biol. Chem., 284, 27281, 10.1074/jbc.M109.022509 · DOI
  25. Wooldridge, 2007, Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region, Eur. J. Immunol., 37, 1323, 10.1002/eji.200636765 · DOI
  26. Garboczi, 1996, Structure of the complex between human T-cell receptor, viral peptide and HLA-A2, Nature, 384, 134, 10.1038/384134a0 · DOI · Paper page
  27. Boulter, 2003, Stable, soluble T-cell receptor molecules for crystallization and therapeutics, Protein Eng., 16, 707, 10.1093/protein/gzg087 · DOI · Paper page
  28. Wyer, 1999, T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics, Immunity, 10, 219, 10.1016/S1074-7613(00)80022-9 · DOI · Paper page
  29. Salter, 1986, Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid, EMBO J., 5, 943, 10.1002/j.1460-2075.1986.tb04307.x · DOI · Paper page
  30. Betts, 2003, Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation, J. Immunol. Methods, 281, 65, 10.1016/S0022-1759(03)00265-5 · DOI · Paper page
  31. Wooldridge, 2009, Tricks with tetramers: how to get the most from multimeric peptide-MHC, Immunology, 126, 147, 10.1111/j.1365-2567.2008.02848.x · DOI · Paper page
  32. Wooldridge, 2005, Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface, J. Biol. Chem., 280, 27491, 10.1074/jbc.M500555200 · DOI · Paper page
  33. Price, 2005, Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses, J. Exp. Med., 202, 1349, 10.1084/jem.20051357 · DOI · Paper page
  34. Lefranc, 2003, IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains, Dev. Comp. Immunol., 27, 55, 10.1016/S0145-305X(02)00039-3 · DOI · Paper page
  35. Rosenberg, 2004, Cancer immunotherapy: moving beyond current vaccines, Nat. Med., 10, 909, 10.1038/nm1100 · DOI · Paper page
  36. Bins, 2007, Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients, J. Immunother., 30, 234, 10.1097/01.cji.0000211333.06762.47 · DOI
  37. Meidenbauer, 2003, Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients, J. Immunol., 170, 2161, 10.4049/jimmunol.170.4.2161 · DOI
  38. Chen, 2005, Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination, Cancer Immun., 5, 5
  39. Clay, 1999, Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue, J. Immunol., 162, 1749, 10.4049/jimmunol.162.3.1749 · DOI
  40. Pass, 1998, Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay, Cancer J. Sci. Am., 4, 316
  41. Rubio, 2003, Ex vivo identification, isolation and analysis of tumor-cytolytic T cells, Nat. Med., 9, 1377, 10.1038/nm942 · DOI · Paper page
  42. Madden, 1993, The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2, Cell, 75, 693, 10.1016/0092-8674(93)90490-H · DOI · Paper page
  43. Guo, 1993, Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A*0201, and HLA-B*2705, Proc. Natl. Acad. Sci. USA, 90, 8053, 10.1073/pnas.90.17.8053 · doi:10.1073/pnas.90.17.8053
  44. Speiser, 2002, In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells, Eur. J. Immunol., 32, 731, 10.1002/1521-4141(200203)32:3<731::AID-IMMU731>3.0.CO;2-H · DOI
  45. Varela-Rohena, 2008, Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor, Nat. Med., 14, 1390, 10.1038/nm.1779 · DOI · Paper page
  46. Borbulevych, 2007, Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition, J. Mol. Biol., 372, 1123, 10.1016/j.jmb.2007.07.025 · DOI
  47. Sliz, 2001, Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes, J. Immunol., 167, 3276, 10.4049/jimmunol.167.6.3276 · DOI
  48. Tynan, 2005, T cell receptor recognition of a ‘super-bulged’ major histocompatibility complex class I-bound peptide, Nat. Immunol., 6, 1114, 10.1038/ni1257 · doi:10.1038/ni1257
  49. Tynan, 2007, A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule, Nat. Immunol., 8, 268, 10.1038/ni1432 · DOI · Paper page
  50. Macdonald, 2009, T cell allorecognition via molecular mimicry, Immunity, 31, 897, 10.1016/j.immuni.2009.09.025 · DOI · Paper page
  51. Wieckowski, 2009, Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients, J. Immunol., 183, 5397, 10.4049/jimmunol.0901460 · DOI
  52. Vignard, 2005, Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells, J. Immunol., 175, 4797, 10.4049/jimmunol.175.7.4797 · DOI
  53. Serana, 2009, Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients, J. Transl. Med., 7, 21, 10.1186/1479-5876-7-21 · doi:10.1186/1479-5876-7-21
  54. Rudolph, 2006, How TCRs bind MHCs, peptides, and coreceptors, Annu. Rev. Immunol., 24, 419, 10.1146/annurev.immunol.23.021704.115658 · DOI · Paper page
  55. Borbulevych, 2005, Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design, J. Immunol., 174, 4812, 10.4049/jimmunol.174.8.4812 · doi:10.4049/jimmunol.174.8.4812
  56. Bowerman, 2009, Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity, Mol. Immunol., 46, 3000, 10.1016/j.molimm.2009.06.012 · DOI
  57. Finke, 2007, Lessons from randomized phase III studies with active cancer immunotherapies—outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC), Vaccine, 25, B97, 10.1016/j.vaccine.2007.06.067 · DOI
  58. Jones, 1996, Therapeutic vaccines for melanoma: progress and problems, Trends Biotechnol., 14, 349, 10.1016/0167-7799(96)10045-7 · doi:10.1016/0167-7799(96)10045-7

Cited by

See all 115

Metadata

Authors
Cole, D. K., Edwards, E. S. J., Wynn, K. K., Clement, M., Miles, J. J., Ladell, K., Ekeruche, J., Gostick, E., Adams, K. J., Skowera, A., Peakman, M., Wooldridge, L., Price, D. A., & Sewell, A. K.
Venue
The Journal of Immunology
Published
2010-08
Volume
185
Issue
4
Pages
2600-2610
ISSN
  • 0022-1767
  • 1550-6606
Cited by
115
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.